In Denmark, Novozymes released their group financial report for 2011, stating Growth in local currencies was 10% compared to 2010. EBIT increased by 11% and took the EBIT margin to 22.3% despite a negative impact from higher raw material prices, acquisitions, and unfavorable currency rates. Net profit grew by 13%, and free cash flow before acquisitions and divestments came in high, supported by the increased net profit.
Steen Riisgaard, President & CEO stated, “To sum up, although 2012 looks to be another uncertain year with respect to the global economy…”

Related Articles
- Novozymes earnings up, despite currency fall; bioenergy sales rise
- Novozymes reports sales, earnings growth for Q3
- Oxygen for High Altitudes: 17 Biofuels ventures raise $434M in equity
- Novozymes, despite disappointing first quarter, promises sales growth in 2012
- Novozymes earnings soar; guidance lifts for 2010
- Novozymes reports 5% lift in sales, 4% earnings growth
- Novozymes expands in China; earnings up 33 percent in Q1, outlook upgraded
- Novozymes, Royal Nedalco partner to optimize fermentation yields for cellulosic ethanol
- Novozymes awarded $18M in patent dispute with Dupont's Danisco unit
- Novozymes reports accelerating profits, but expresses concerns over US biofuels market
- Novozymes sues Danisco over alpha-amylase patent infringement
- Novozymes joins Monsanto, Bunge in Nidus investment arm
- Novozymes: retain US ethanol tax incentives
- US has 3 percent of oil reserves, 25 percent of ag residue reserves
- Novozymes, DONG debut new biorefining process
Tags: Novozymes
Category: International
Comments (0)
Trackback URL | Comments RSS Feed
There are no comments yet. Why not be the first to speak your mind.